Skin care formulations and skin cancer treatment
Inventors
Bode, Ann M. • Dong, Zigang • Roh, Eunmiri
Assignees
University of Minnesota System
Publication Number
US-12233073-B2
Publication Date
2025-02-25
Expiration Date
2038-06-08
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
An example technique for treating a skin cancer condition includes administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer. An example composition includes a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition. An example composition includes a pharmaceutically effective amount of at least one anti-solar ultraviolet (anti-sUV) combination for preventing a skin cancer condition. The at least one anti-sUV combination is chosen from the combinations: avobenzone and octinoxate; octocrylene and zinc oxide; avobenzone, octocrylene, and titanium dioxide; or avobenzone, octocrylene, and zinc oxide.
Core Innovation
The invention provides techniques and compositions for treating skin cancer conditions by administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to patients diagnosed with skin cancer or at high risk of developing skin cancer. Specific PRPK inhibitors such as rocuronium bromide and betamethasone 17-valerate, as well as their analogs and derivatives, may be utilized in these treatments. These inhibitors function by targeting the PRPK pathway, which is associated with T-LAK cell-originated protein kinase (TOPK)-dependent PRPK phosphorylation, a critical process in skin cancer development.
Additionally, the patent discloses compositions including pharmaceutically effective combinations of anti-solar ultraviolet (anti-sUV) agents for the prevention of skin cancer. These combinations are specifically chosen for their efficacy, including but not limited to avobenzone and octinoxate; octocrylene and zinc oxide; avobenzone, octocrylene, and titanium dioxide; or avobenzone, octocrylene, and zinc oxide. The effectiveness of these combinations is measured by their ability to significantly reduce sUV-induced tumor formation and volume.
The invention also encompasses noncarcinogenic skin care formulations comprising defined first and second phases containing humectants, chelating agents, emollients, and stabilizers, with a focus on avoiding allergenic preservatives. These formulations can optionally include anti-aging or anti-wrinkling agents and can be used as topical carriers for PRPK inhibitors or anti-sUV combinations, thus serving both preventative and therapeutic functions in skin care and skin cancer management.
This technology addresses the problem of high and rising incidence rates of non-melanoma skin cancers (NMSC), such as squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), which are primarily induced by solar ultraviolet exposure. Conventional treatments like surgery may be ineffective against recurrences, and existing skin care formulations can potentially be carcinogenic or have undesirable side effects. The disclosed compositions and techniques aim to reduce the development, volume, and number of skin tumors by direct treatment and improved sun protection while maintaining skin health.
Claims Coverage
The patent includes several independent inventive features related to the treatment and prevention of skin cancer using PRPK inhibitors, anti-solar ultraviolet combinations, and noncarcinogenic skin care compositions.
Method of treating skin cancer using PRPK inhibitor comprising rocuronium bromide or analogs
A method for treating a skin condition, particularly skin cancer or high-risk precursors, by administering a composition that contains a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor. The composition specifically includes 0.1% to 1% (weight/volume) of the PRPK inhibitor, where the PRPK inhibitor comprises rocuronium bromide or analogs thereof. This inventive method covers: - Treatment of skin conditions such as actinic keratosis, squamous cell carcinoma, or basal cell carcinoma - Administration via a pharmaceutically acceptable carrier, including topical lotions or emulsions - Optionally measuring phosphorylated PRPK levels pre- and post-treatment and adjusting dosage accordingly - The PRPK inhibitor may be combined with additional treatments, such as chemotherapy or radiotherapy
Method for treating actinic keratosis using PRPK inhibitor
A specific application of the general method where the treated condition is actinic keratosis. The method involves administering a composition with 0.1% to 1% (weight/volume) PRPK inhibitor comprising rocuronium bromide or analogs to a patient with actinic keratosis. The preferred carrier is a lotion or oil in water emulsion that may contain specific excipients such as a salt of ethylenediamine tetra-acetic acid (EDTA), 1,3-butylene glycol, glycerin, pentylene glycol, cetyl alcohol, glyceryl stearate, and hydrogenated polydecene.
The claims provide broad protection for methods of treating skin cancer and precancer using PRPK inhibitors, specifically rocuronium bromide or analogs, in specified concentrations and carriers, as well as preventive and therapeutic compositions for actinic keratosis. The inventive features extend to both composition and method-of-use claims, including detailed administration and formulation aspects.
Stated Advantages
Treatment with the disclosed PRPK inhibitors reduces both the number and volume of skin tumors.
The compositions can provide high effectiveness in preventing sUV-induced skin cancer when using specific anti-sUV combinations.
The skin care formulations are noncarcinogenic and do not promote the development of skin cancer upon UV exposure.
Compositions are formulated to minimize the risk of allergenic reactions by avoiding known allergenic preservatives.
Formulations may incorporate optional anti-aging or anti-wrinkling agents and can be used as a base for other skin care preparations.
The compositions do not exhibit phototoxicity when applied with or without exposure to solar UV irradiation.
The use of PRPK inhibitors, specifically rocuronium bromide and betamethasone 17-valerate, may upregulate beneficial immune responses relevant to cancer prevention.
Documented Applications
Use in the treatment of skin cancer conditions, including actinic keratosis, squamous cell carcinoma, and basal cell carcinoma.
Prevention of skin cancer in patients at high risk of developing skin cancer.
Topical treatment of actinic keratosis using lotions or emulsions containing PRPK inhibitors.
Application of skin care formulations as noncarcinogenic cosmetic creams or lotions for general skin health.
Prevention of sUV-induced tumor formation through topical application of specific anti-solar ultraviolet agent combinations.
Interested in licensing this patent?